• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

生物治疗性蛋白质的稳定性问题:早期评估作为缓解策略。

Stability liabilities of biotherapeutic proteins: Early assessment as mitigation strategy.

机构信息

Instituto de Biologia Experimental e Tecnológica, Apartado 12, 2781-901 Oeiras, Portugal.

Novartis Pharma AG, 4056 Basel, Switzerland.

出版信息

J Pharm Biomed Anal. 2021 Jan 5;192:113650. doi: 10.1016/j.jpba.2020.113650. Epub 2020 Sep 25.

DOI:10.1016/j.jpba.2020.113650
PMID:33065403
Abstract

Identification of molecular liabilities and implementation of mitigation strategies are key aspects that need to be considered by pharmaceutical companies developing therapeutic proteins. In the field of monoclonal antibodies, an efficient and streamlined process known as developability assessment is used for the selection of the "fittest" candidate. Other protein modalities, have in most cases only a limited number of possible candidates, requiring a paradigm change to a concept of candidate enabling. The assessment of liabilities at early project phases with the possibility to re-engineer candidates becomes essential for the success of these projects. Each protein possesses a unique stability profile resulting from the interplay of conformational, colloidal, chemical and physical stability attributes. All of these attributes strongly depend on external factors. Conformational and colloidal stability profiles of three non-immunoglobulin domain based proteins, namely Carbonic anhydrase, Ovalbumin and Thyroglobulin, and of two monoclonal antibodies were assessed in dependence of solution pH, ionic strength and varying buffering agents. The impact of screened external factors on proteins' stability attributes varied significantly, indicating presence of molecule specific liabilities. Screening of such a broad space of conditions at early project phases is only feasible using low-material consuming, high-throughput analytical methods as exemplified in this study.

摘要

鉴定分子缺陷并实施缓解策略是制药公司开发治疗性蛋白时需要考虑的关键方面。在单克隆抗体领域,有一种称为可开发性评估的高效简化流程,用于选择“最合适”的候选物。其他蛋白质形式在大多数情况下只有数量有限的可能候选物,需要将概念从候选物选择转变为候选物设计。在早期项目阶段评估缺陷,并有可能对候选物进行重新设计,这对于这些项目的成功至关重要。每种蛋白质都具有独特的稳定性特征,这是由构象、胶体、化学和物理稳定性属性相互作用的结果。所有这些属性都强烈依赖于外部因素。本文评估了三种非免疫球蛋白结构域蛋白(即碳酸酐酶、卵清蛋白和甲状腺球蛋白)和两种单克隆抗体的构象和胶体稳定性特征,这些蛋白的稳定性特征取决于溶液 pH 值、离子强度和不同的缓冲剂。筛选出的外部因素对蛋白质稳定性属性的影响差异很大,表明存在分子特异性缺陷。只有使用低材料消耗、高通量的分析方法(如本研究所示),才能在早期项目阶段筛选如此广泛的条件。

相似文献

1
Stability liabilities of biotherapeutic proteins: Early assessment as mitigation strategy.生物治疗性蛋白质的稳定性问题:早期评估作为缓解策略。
J Pharm Biomed Anal. 2021 Jan 5;192:113650. doi: 10.1016/j.jpba.2020.113650. Epub 2020 Sep 25.
2
Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection.使用泰勒分散分析和紫外区域成像检测对治疗性抗体候选物进行早期可开发性筛选。
MAbs. 2015;7(1):77-83. doi: 10.4161/19420862.2014.985544.
3
Predicting Antibody Developability Profiles Through Early Stage Discovery Screening.通过早期发现筛选预测抗体可开发性特征。
MAbs. 2020 Jan-Dec;12(1):1743053. doi: 10.1080/19420862.2020.1743053.
4
Analytical Workflows to Unlock Predictive Power in Biotherapeutic Developability.生物治疗开发可预测性分析工作流程的解锁。
Pharm Res. 2023 Feb;40(2):487-500. doi: 10.1007/s11095-022-03448-y. Epub 2022 Dec 5.
5
Advancing Therapeutic Protein Discovery and Development through Comprehensive Computational and Biophysical Characterization.通过全面的计算和生物物理特性分析来推进治疗性蛋白的发现和开发。
Mol Pharm. 2020 Feb 3;17(2):426-440. doi: 10.1021/acs.molpharmaceut.9b00852. Epub 2020 Jan 7.
6
Prediction of colloidal stability of high concentration protein formulations.高浓度蛋白质制剂的胶体稳定性预测
Pharm Dev Technol. 2015 May;20(3):367-74. doi: 10.3109/10837450.2013.871032. Epub 2014 Jan 6.
7
Developability assessment for monoclonal antibody drug candidates: a case study.单克隆抗体药物候选物的可开发性评估:案例研究。
Pharm Dev Technol. 2021 Jan;26(1):11-20. doi: 10.1080/10837450.2020.1829641. Epub 2020 Oct 14.
8
Susceptibility of Antibody CDR Residues to Chemical Modifications Can Be Revealed Prior to Antibody Humanization and Aid in the Lead Selection Process.抗体 CDR 残基对化学修饰的敏感性可以在抗体人源化之前揭示出来,并有助于先导化合物的选择过程。
Mol Pharm. 2018 Oct 1;15(10):4529-4537. doi: 10.1021/acs.molpharmaceut.8b00536. Epub 2018 Aug 29.
9
Blueprint for antibody biologics developability.抗体生物制剂开发蓝图。
MAbs. 2023 Jan-Dec;15(1):2185924. doi: 10.1080/19420862.2023.2185924.
10
Early engineering approaches to improve peptide developability and manufacturability.早期改善肽类药物可开发性和可制造性的工程学方法。
AAPS J. 2015 Jan;17(1):111-20. doi: 10.1208/s12248-014-9681-9. Epub 2014 Oct 23.

引用本文的文献

1
Predicting and Interpreting Protein Developability Via Transfer of Convolutional Sequence Representation.通过卷积序列表示的转移来预测和解释蛋白质可开发性。
ACS Synth Biol. 2023 Sep 15;12(9):2600-2615. doi: 10.1021/acssynbio.3c00196. Epub 2023 Aug 29.
2
Molecular engineering of cyclic azobenzene-peptide hybrid ligands for the purification of human blood Factor VIII via photo-affinity chromatography.用于通过光亲和色谱法纯化人血因子VIII的环状偶氮苯-肽杂合配体的分子工程。
Adv Funct Mater. 2023 Apr 4;33(14). doi: 10.1002/adfm.202213881. Epub 2023 Jan 25.
3
Pre-Clinical In-Vitro Studies on Parameters Governing Immune Complex Formation.
关于免疫复合物形成相关参数的临床前体外研究
Pharmaceutics. 2022 Jun 13;14(6):1254. doi: 10.3390/pharmaceutics14061254.
4
Intrinsic physicochemical profile of marketed antibody-based biotherapeutics.市售抗体类生物治疗药物的固有物理化学特性。
Proc Natl Acad Sci U S A. 2021 Sep 14;118(37). doi: 10.1073/pnas.2020577118.